Skip to content
Home/Companies/Healthcare/PharmaReview
PharmaReview

PharmaReview

Healthcare·UK·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns PharmaReview?

PharmaReview is currently owned by Bridgepoint through Growth II (BG II) (2024 vintage), since 2021.

Hand-verified · 3 sources · updated 2026-04-21

Bridgepoint
Investor
Bridgepoint
Growth II (BG II) · 2024 · Growth

Key facts

HQUK
SectorHealthcare
Websitepharmareview.com

More from Growth II (BG II)

Other portfolio companies in the same fund.

Exile Group
Active
Business ServicesUK· 2026
Chime Software
Active
TMTUK· 2025
Zuto
Zuto
Active
FinancialsUK· 2025
Condatis
Condatis
Active
TMTUK· 2024
Identicare
Active
HealthcareUK· 2024
Surikat
Active
TMTSweden· 2024

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
A Place for Mom
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Track PharmaReview

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on PharmaReview.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

6 verified KPIs (Revenue, EBITDA, growth)
Hand-checked deal notes on this investment
3 source links for every datapoint
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue